EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins

Vikrama Raja, Carlos Aguiar, Nasreen Alsayed, Yogeyaa S Chibber, Hussein ElBadawi, Michel Farnier, Kumari Pushpa, Lale Tokgözoglu, Alberto Zambon, Jean-Pascal Berrou, Michel P Hermans

Frontiers in Cardiovascular Medicine · 04.06.2026 · 13

DOI: 10.3389/fcvm.2026.1837004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 04.06.2026. Verfasst von Vikrama Raja und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Affairs, Abbott Products Operations AG, Basel, Switzerland. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dyslipidemia, a key risk factor for atherosclerotic cardiovascular disease (ASCVD), is conventionally managed by lowering low-density lipoprotein cholesterol (LDL-C) level. However, even with on-target LDL-C and optimal control of traditional risk factors such as hypertension and diabetes, a substantial residual risk of major adverse cardiovascular events (MACE) persists. A growing body of evidence suggests that remnant cholesterol (RC) – the cholesterol content of triglyceride-rich lipoproteins (TRLs) – partially contributes to this residual risk. Consequently, non-high-density lipoprotein cholesterol (non-HDL-C) is considered a better measure of the ASCVD risk and a comprehensive treatment goal for dyslipidemia. Statin therapy, the standard care for dyslipidemia management, falls short of mitigating RC-related residual risk. The global rise in obesity, type 2 diabetes, and metabolic syndrome has led to a growing prevalence of hypertriglyceridemia, underscoring the need for adjunctive therapies that target TRLs and lower non-HDL-C levels. Fenofibrate, a well-established TRL-lowering agent, has demonstrated efficacy in reducing non-HDL-C when used in combination with statins. Evidence from clinical trials and real-world studies suggests potential benefits of this combination in reducing cardiovascular risk, particularly in patients with elevated triglyceride levels. Moreover, long-term studies – spanning up to two decades –have affirmed the safety and tolerability of fenofibrate, reinforcing its role as a valuable add-on therapy to address remnant cholesterol and residual cardiovascular risk.

Schlagwörter

Stichwörter der Autor:innen

dyslipidemiafenofibratenon-High density lipoprotein cholesterolremnant cholesterolresidual cardiovascular risktriglyceridetriglyceride-rich lipoproteins

Autor:innen und Institutionen

  • Medical Affairs, Abbott Products Operations AG, Basel, Switzerland.
  • Department of Cardiology, Hospital Santa Cruz, Western Lisbon Local Health Unit, Lisbon, Portugal.
  • Department of Endocrinology, Diabetes & Metabolism, Dar Alsaha Medical Center, Manama, Kingdom of Bahrain.
  • Medical Affairs, WNS Global Services, Noida, India.
  • Internal Medicine Department, Wayne State University, Detroit, MI, U.S.A.
  • Metabolic Unit, My Clinic International, Jeddah, Saudi Arabia.

Zitieren

APA

Raja, V., Aguiar, C., Alsayed, N., Chibber, Y. S., ElBadawi, H., Farnier, M., Pushpa, K., Tokgözoglu, L., Zambon, A., Berrou, J. P., & Hermans, M. P. (2026). Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1837004

Vancouver

Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Farnier M, et al. Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1837004

BibTeX
@article{Raja2026,
  author = {Raja, Vikrama and Aguiar, Carlos and Alsayed, Nasreen and Chibber, Yogeyaa S and ElBadawi, Hussein and Farnier, Michel and Pushpa, Kumari and Tokgözoglu, Lale and Zambon, Alberto and Berrou, Jean-Pascal and Hermans, Michel P},
  title = {Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcvm.2026.1837004}
}
Kostenlos starten →